广西百色地区肝病患者及受血者HCV感染现状调查

笔者应用ＥＬＩＳＡ法对广西百色地区１７９例各类肝病患者及４１例受血者血清进行了抗－ＨＣＶ检测。结果各类肝病抗－ＨＣＶ阳性率为１７．９％，受血者抗－ＨＣＶ阳性率为３１．７％。在急性肝炎（急肝）、慢性肝炎（慢肝）、肝硬化和肝癌中，抗－ＨＣＶ阳性率各为４．３％（１／２３）、１２．８％（１０／７８）、２８．６％（１２／４２）和２５．０％（９／３６）。抗－ＨＣＶ阳性率有随肝病慢性比而增高的趋势，肝硬化的抗－ＨＣＶ阳性率明显高于急肝或慢肝（Ｐ＜０．０５），而肝癌的抗－ＨＣＶ阳性率与急肝或慢肝相差不显著（Ｐ＞０．０５或０．１），且发现ＨＢｓＡｇ阴性肝病者的抗－ＨＣＶ阳性率明显高于ＨＢｓＡｇ阳性患者（Ｐ＜０．５），肝病患者抗－ＨＣＶ的检出率与ＡＬＴ活性无关（Ｐ＞０．０５）。在受血者中，抗－ＨＣＶ的检出率与受血次数、ＡＬＴ活性关系非常密切。因此，加强对ＨＣＶ的检测是当前预防输血后肝炎的紧迫任务。     

正交设计在确定混合血清法检测丙型肝炎抗体实验条件中的应用

目的探讨封闭温度、时间、ＢＳＡ浓度、Ｔｗｅｎ２０浓度及混合标本个数５因素各２水平对混合血清法检测抗－ＨＣＶ的影响。方法应用正交设计的方法进行实验分组，采用ＥＩＡ法检测抗－ＨＣＶ。结果封闭条件为０．５％ＢＳＡ，３７℃，３０ｍｉｎ；洗涤液为０．１５％Ｔｗｅｅｎ２０，混合标本个数为５。采用正交设计的实验方法可减少７５％的实验次数。结论在进行多因素的实验研究时，正交设计是一种高效的设计方法。     

统计有偿和无偿献血者HBsAg抗—HCV与抗—HIV检测结果及比较

目的：了解有偿和无偿献者HBsAg、抗－HCV、抗-HIV I/II测定结果。方法：均采用酶联吸附试验（ELISA）法。结果：有偿和无偿献血者之HBsAg阳性率分别为2.39％和3.32％,抗－HCV阳性率分别为4.81％和2.89％,抗－HIV I／II结果均为阴性。结论：有偿与无偿献血者之间的HBsAg和抗－HCV阳性率比较均有显著性差异（t值分别为2.8633和2.3638,P＜0.05）。     

Vertical transmission of hepatitis C Virus: An epidemiological study on 2,980 pregnant women in Italy

The risk of mother-to-infant transmission of hepatitis C virus (HCV) varies according to the population studied and the tests used. Aim of the current study was to investigate HCV vertical transmission rate in children born to 30 HCV positive/HIV negative pregnant women in Italy. We investigated the potential vertical transmission of HCV by identifying HCV antibody seropositive pregnant women, by analyzing HCV-RNA in the peripheral blood using PCR and by prospectively following their offspring until 24 months of age. During the third trimester, 2,980 consecutive pregnant women were examined for anti-HCV antibodies by a second generation Enzyme-Linked Immunosorbent Assay (EIA2) and re-assayed by a second generation Recombinant Immunoblot Assay (RIBA2). A total of 32 mothers (1.07%) were positive for EIA2 test; 30 out of 32 had a reactive confirmatory RIBA2 test for HCV All anti-HCV positive mothers were negative for HIV. These 30 mothers and their 30 babies formed the study cohort. Of the 30 anti-HCV positive mothers, 10 were also positive for serum HCV-RNA by PCR. All the babies born to the 30 anti-HCV positive mothers were initially negative for HCV-RNA (cord blood specimens), but three babies became positive at three months of age and remained positive thereafter. These babies had been born to 3 of the 10 mothers with viremia during the third trimester of pregnancy. These results suggest that HCV vertical transmission is possible in 10% of anti-HCV positives and in about 33% of the HCV-RNA seropositive mothers.     

丙型肝炎诊断试剂的研究

本文用分子生物学方法根据中国人HCV基因特点进行多肽合成,研究丙型肝炎C区、E区酶标试剂的临床应用以及与抗C 100-3试剂的比较,并以 RT双 PCR的方法建立了HCV RNA的检测试剂及临床应用。结果发现抗-CP试剂敏感性、特异性均优于抗C100-3,从临床检测结果看,在自然人群中感染率抗-CP为2.8％,抗C100-3为2.1％,特别在输血后肝炎中,抗 CP阳性率高达 71.7％～75.9％。因此提出对HCV的诊断确立与愈后判断各类试剂有各自的作用,不能只根据某一试剂的某一次结果而简单地否定 HCV感染。HCV RNA测定,建立了5’末端非编码区及非结构区(NS 1),采用双PCR观察结果抗-CP阳性者绝大多数为RNA阳性,并提示将有助于抗病毒药物疗效的观察指标。     

Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus

Objective: To evaluate the clinical, biochemical, and virologic features associated with hepatitis C virus (HCV) infection acquired early in life from mothers with antibodies to HCV (anti-HCV).Study design: Multicenter prospective-retrospective study in Italian children.Patients: Two groups of children were investigated. Group 1 included 14 infants, born to mothers with anti-HCV but without human immunodeficiency virus infection, who became seropositive for HCV RNA during the first year of life and were thus considered infected. Group 2 included 16 children with chronic hepatitis C, aged 1 ½ to 14 years, whose mothers were the unique potential source of infection. Both groups were followed for 12 to 48 months.Methods: Alanine transaminase (ALT), anti-HCV, and HCV RNA were investigated by the polymerase chain reaction on entry to the study and during follow-up.Results: All children in group 1 had anti-HCV throughout follow-up, and all had ALT abnormalities, ranging from 1.5 to 10.5 times the normal value during the first 12 months. During further follow-up, 5 of 10 children had HCV RNA with abnormal ALT values, 3 had a return to normal of the ALT values but continued to have viremia, and 2 eventually had normal ALT values and clearance of HCV RNA. Of the 16 children in group 2, all were free of symptoms and 62% had only slight ALT elevations; 7 who underwent liver biopsy had histologic features of minimal or moderate hepatitis.Conclusions: HCV infection acquired early in life from mothers with anti-HCV is usually associated with biochemical features of liver damage during the first 12 months of life. Progression to chronicity seems to occur in the majority of cases, although HCV-associated liver disease is likely to be mild throughout infancy and childhood. (J Pediatr 1997;130:990-3)     

西安市无偿献血人群血液检测结果与肝炎流行病学分析

目的探讨西安市无偿献血人群中血液检测不合格数与肝炎病毒感染的关系。方法采用统计学方法对2000-2004年血液检测不合格结果进行分析。结果定性资料多个样本率比较结果显示,5年检出率的差异有显著性（P〈0．05）。结论检出率可能是对西安地区18～55岁健康人群中无症状肝炎流行病学的一种评估。     

河南省2012－2014年新报告HIV感染者中HCV抗体流行状况分析

目的 了解河南省2012－2014年新报告HIV感染者中HCV抗体的流行情况。方法 通过艾滋病综合防治数据信息管理系统对河南省2012年7月1日至2014年6月30日新报告的HIV感染者进行信息整理、HIV-1 BED新发感染检测和HCV抗体检测。结果 4 267例新报告HIV感染者中HCV抗体阳性率为13.19%(563/4 267),感染途径为注射吸毒者的HCV抗体阳性率最高(77.27%),采血浆/输血、异性性传播、同性性传播和母婴传播人群的HCV抗体阳性率分别为15.06%、15.81%、3.74%和8.96%。开封(32.04%)、驻马店(25.00%)、商丘(25.00%)、周口(18.86%)和南阳(14.67%)为HCV抗体阳性率最高的前五个省辖市。BED阳性者(HIV新近感染者)中HCV抗体阳性率为7.50%(86/1 146)。多因素logistic回归分析发现:BED阴性、年龄>40岁、农民、HIV感染途径为注射吸毒以及报告地区为开封市、南阳市、商丘市、驻马店市和周口市为HCV感染的危险因素。结论 2012－2014年河南省新报告HIV感染者中HCV抗体流行率有降低的趋势,但是部分地区和重点人群仍存在较高的HCV抗体流行率。     

Prevalence of false-positive hepatitis C antibody results,National Health and Nutrition Examination Study (NHANES) 2007–2012

BackgroundScreening large numbers of persons in a population with low prevalence of a disease leads to many false-positives. However, populations with low HCV prevalence may sometimes be recommended for HCV screening, for instance patients or healthcare workers after a possible healthcare-related exposure.ObjectivesWe determined the percentage of true vs false-positive HCV antibody (anti-HCV) test results among 2007–2012 participants in the National Health and Nutrition Examination Study (NHANES), a nationally representative study with approximately 1% HCV infection prevalence, much lower than in groups typically recommended for HCV screening.Study designAnti-HCV test confirmation was performed using a recombinant immunoblot assay (RIBA) test and follow-up HCV RNA testing.ResultsOverall, of 22,359 NHANES participants tested, 479 (2%) were anti-HCV screening reactive and 477 were tested for RIBA; of these 323 (68%) confirmed as true positive and 105 (22%) were false-positives. Many others (49, 10%) were RIBA indeterminate and likely false-positive. Because of these false positive tests, the overall prevalence of chronic infection among those testing anti-HCV screening reactive was much lower (218, 51%) than would be expected due to disease clearance alone (approximately 80%).ConclusionsAll screening anti-HCV positive tests should be followed by an HCV RNA test, in order to confirm whether the patient has current infection so that infected persons can be referred to care and treatment to avoid the significant morbidity and mortality associated with chronic HCV infection.